Artelo Biosciences
ARTL
8 hedge funds and large institutions have $830K invested in Artelo Biosciences in 2026 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 1 increasing their positions, reducing their positions, and 5 closing their positions.
588% more capital invested
Capital invested by funds: $121K → $830K (+$709K)
40% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 5
14% more funds holding
Funds holding: 7 → 8 (+1)
1.44% more ownership
Funds ownership: 4.88% → 6.32% (+1.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Kathmere Capital Management
Wayne,
Pennsylvania
|
+$62.7K |
| 2 |
Jane Street
New York
|
+$61.8K |
| 3 |
Citigroup
New York
|
+$14.6K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$10.4K |
| 5 |
AS
Altshuler Shaham
Tel Aviv,
Israel
|
+$4.21K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$41K |
| 2 |
Two Sigma Investments
New York
|
-$25.2K |
| 3 |
VF
Virtu Financial
New York
|
-$21K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$13.9K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$21 |
ARTL Hedge Fund Activity: Q1 2026 in Review
8 of the 8,203 institutional investors tracked by Wall St. Rank reported a position in Artelo Biosciences (ARTL) for Q1 2026, worth a combined $830K — up 588% from $121K a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new ARTL positions and 5 closed out — a net gain of 2 holders — while 1 added to existing stakes and 0 trimmed.
The largest buyer was Kathmere Capital Management, opening a new position worth an estimated $62.7K. The largest seller was UBS Group, exiting entirely with an estimated $41K sold.
- 8 institutional investors held Artelo Biosciences (ARTL) as of Q1 2026, up from 7 in Q4 2025.
- Funds reported $830K of Artelo Biosciences stock for Q1 2026, up 588% quarter-over-quarter.
- 7 funds opened new Artelo Biosciences positions in Q1 2026 and 5 closed out, a net change of +2 holders.
- The largest Artelo Biosciences buyer in Q1 2026 was Kathmere Capital Management, an estimated $62.7K added.
- The largest Artelo Biosciences seller in Q1 2026 was UBS Group, an estimated $41K sold.
Based on aggregated 13F filings for Q1 2026.